ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Next Generation Cancer Diagnostics Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-24F2154
Home | Market Reports | Health| Health Conditions| Cancer
Global Next Generation Cancer Diagnostics Market Insights and Forecast to 2028
BUY CHAPTERS

Global Next Generation Cancer Diagnostics Market Research Report 2025

Code: QYRE-Auto-24F2154
Report
September 2025
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Cepheid Inc
Koninklijke Philips N V
F Hoffmann La Roche Ltd
Qiagen NV
Novartis
Abbott
Thermo Fisher Scientific
OPKO Health
Myriad Genetics
Agilent Technologies
GE Healthcare
PerkinElmer Inc
Genomic Health
Illumina Inc
Hologic Inc
Almac Group
Janssen Global Services
Sysmex Corporation

Next Generation Cancer Diagnostics Market Size

The global market for Next Generation Cancer Diagnostics was valued at US$ 8826 million in the year 2024 and is projected to reach a revised size of US$ 28510 million by 2031, growing at a CAGR of 18.5% during the forecast period.

Next Generation Cancer Diagnostics Market

Next Generation Cancer Diagnostics Market

North American market for Next Generation Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Next Generation Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Next Generation Cancer Diagnostics in Hospitals is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Next Generation Cancer Diagnostics include Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Next Generation Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next Generation Cancer Diagnostics.
The Next Generation Cancer Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Next Generation Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next Generation Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Next Generation Cancer Diagnostics Market Report

Report Metric Details
Report Name Next Generation Cancer Diagnostics Market
Accounted market size in year US$ 8826 million
Forecasted market size in 2031 US$ 28510 million
CAGR 18.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Next Generation Sequencing
  • qPCR & Multiplexing
  • DNA Microarrays
  • Others
Segment by Application
  • Hospitals
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, GE Healthcare, PerkinElmer, Genomic Health, Illumina, Hologic, Almac Group, Janssen Global Services, Sysmex Corporation
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Next Generation Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Next Generation Cancer Diagnostics Market growing?

Ans: The Next Generation Cancer Diagnostics Market witnessing a CAGR of 18.5% during the forecast period 2025-2031.

What is the Next Generation Cancer Diagnostics Market size in 2031?

Ans: The Next Generation Cancer Diagnostics Market size in 2031 will be US$ 28510 million.

Who are the main players in the Next Generation Cancer Diagnostics Market report?

Ans: The main players in the Next Generation Cancer Diagnostics Market are Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, GE Healthcare, PerkinElmer, Genomic Health, Illumina, Hologic, Almac Group, Janssen Global Services, Sysmex Corporation

What are the Application segmentation covered in the Next Generation Cancer Diagnostics Market report?

Ans: The Applications covered in the Next Generation Cancer Diagnostics Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Next Generation Cancer Diagnostics Market report?

Ans: The Types covered in the Next Generation Cancer Diagnostics Market report are Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Next Generation Sequencing
1.2.3 qPCR & Multiplexing
1.2.4 DNA Microarrays
1.2.5 Others
1.3 Market by Application
1.3.1 Global Next Generation Cancer Diagnostics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Cancer Diagnostics Market Perspective (2020-2031)
2.2 Global Next Generation Cancer Diagnostics Growth Trends by Region
2.2.1 Global Next Generation Cancer Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Next Generation Cancer Diagnostics Historic Market Size by Region (2020-2025)
2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Region (2026-2031)
2.3 Next Generation Cancer Diagnostics Market Dynamics
2.3.1 Next Generation Cancer Diagnostics Industry Trends
2.3.2 Next Generation Cancer Diagnostics Market Drivers
2.3.3 Next Generation Cancer Diagnostics Market Challenges
2.3.4 Next Generation Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Cancer Diagnostics Players by Revenue
3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2020-2025)
3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2020-2025)
3.2 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Next Generation Cancer Diagnostics Revenue
3.4 Global Next Generation Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2024
3.5 Global Key Players of Next Generation Cancer Diagnostics Head office and Area Served
3.6 Global Key Players of Next Generation Cancer Diagnostics, Product and Application
3.7 Global Key Players of Next Generation Cancer Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Cancer Diagnostics Breakdown Data by Type
4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2020-2025)
4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2026-2031)
5 Next Generation Cancer Diagnostics Breakdown Data by Application
5.1 Global Next Generation Cancer Diagnostics Historic Market Size by Application (2020-2025)
5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Next Generation Cancer Diagnostics Market Size (2020-2031)
6.2 North America Next Generation Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Next Generation Cancer Diagnostics Market Size by Country (2020-2025)
6.4 North America Next Generation Cancer Diagnostics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next Generation Cancer Diagnostics Market Size (2020-2031)
7.2 Europe Next Generation Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Next Generation Cancer Diagnostics Market Size by Country (2020-2025)
7.4 Europe Next Generation Cancer Diagnostics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Cancer Diagnostics Market Size (2020-2031)
8.2 Asia-Pacific Next Generation Cancer Diagnostics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2020-2025)
8.4 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next Generation Cancer Diagnostics Market Size (2020-2031)
9.2 Latin America Next Generation Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Next Generation Cancer Diagnostics Market Size by Country (2020-2025)
9.4 Latin America Next Generation Cancer Diagnostics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Cancer Diagnostics Market Size (2020-2031)
10.2 Middle East & Africa Next Generation Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2020-2025)
10.4 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cepheid
11.1.1 Cepheid Company Details
11.1.2 Cepheid Business Overview
11.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
11.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.1.5 Cepheid Recent Development
11.2 Koninklijke Philips N.V
11.2.1 Koninklijke Philips N.V Company Details
11.2.2 Koninklijke Philips N.V Business Overview
11.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
11.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.2.5 Koninklijke Philips N.V Recent Development
11.3 F. Hoffmann-La Roche Ltd
11.3.1 F. Hoffmann-La Roche Ltd Company Details
11.3.2 F. Hoffmann-La Roche Ltd Business Overview
11.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
11.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.3.5 F. Hoffmann-La Roche Ltd Recent Development
11.4 Qiagen
11.4.1 Qiagen Company Details
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
11.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.4.5 Qiagen Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
11.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.5.5 Novartis AG Recent Development
11.6 Abbott
11.6.1 Abbott Company Details
11.6.2 Abbott Business Overview
11.6.3 Abbott Next Generation Cancer Diagnostics Introduction
11.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.6.5 Abbott Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Details
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
11.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Opko Health
11.8.1 Opko Health Company Details
11.8.2 Opko Health Business Overview
11.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
11.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.8.5 Opko Health Recent Development
11.9 Myriad Genetics
11.9.1 Myriad Genetics Company Details
11.9.2 Myriad Genetics Business Overview
11.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
11.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.9.5 Myriad Genetics Recent Development
11.10 Agilent Technologies
11.10.1 Agilent Technologies Company Details
11.10.2 Agilent Technologies Business Overview
11.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
11.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.10.5 Agilent Technologies Recent Development
11.11 GE Healthcare
11.11.1 GE Healthcare Company Details
11.11.2 GE Healthcare Business Overview
11.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
11.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.11.5 GE Healthcare Recent Development
11.12 PerkinElmer
11.12.1 PerkinElmer Company Details
11.12.2 PerkinElmer Business Overview
11.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
11.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.12.5 PerkinElmer Recent Development
11.13 Genomic Health
11.13.1 Genomic Health Company Details
11.13.2 Genomic Health Business Overview
11.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
11.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.13.5 Genomic Health Recent Development
11.14 Illumina
11.14.1 Illumina Company Details
11.14.2 Illumina Business Overview
11.14.3 Illumina Next Generation Cancer Diagnostics Introduction
11.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.14.5 Illumina Recent Development
11.15 Hologic
11.15.1 Hologic Company Details
11.15.2 Hologic Business Overview
11.15.3 Hologic Next Generation Cancer Diagnostics Introduction
11.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.15.5 Hologic Recent Development
11.16 Almac Group
11.16.1 Almac Group Company Details
11.16.2 Almac Group Business Overview
11.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
11.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.16.5 Almac Group Recent Development
11.17 Janssen Global Services
11.17.1 Janssen Global Services Company Details
11.17.2 Janssen Global Services Business Overview
11.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
11.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.17.5 Janssen Global Services Recent Development
11.18 Sysmex Corporation
11.18.1 Sysmex Corporation Company Details
11.18.2 Sysmex Corporation Business Overview
11.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
11.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2020-2025)
11.18.5 Sysmex Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Cepheid Inc
Koninklijke Philips N V
F Hoffmann La Roche Ltd
Qiagen NV
Novartis
Abbott
Thermo Fisher Scientific
OPKO Health
Myriad Genetics
Agilent Technologies
GE Healthcare
PerkinElmer Inc
Genomic Health
Illumina Inc
Hologic Inc
Almac Group
Janssen Global Services
Sysmex Corporation
List of Tables
 Table 1. Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Next Generation Sequencing
 Table 3. Key Players of qPCR & Multiplexing
 Table 4. Key Players of DNA Microarrays
 Table 5. Key Players of Others
 Table 6. Global Next Generation Cancer Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Next Generation Cancer Diagnostics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Next Generation Cancer Diagnostics Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Next Generation Cancer Diagnostics Market Share by Region (2020-2025)
 Table 10. Global Next Generation Cancer Diagnostics Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Next Generation Cancer Diagnostics Market Share by Region (2026-2031)
 Table 12. Next Generation Cancer Diagnostics Market Trends
 Table 13. Next Generation Cancer Diagnostics Market Drivers
 Table 14. Next Generation Cancer Diagnostics Market Challenges
 Table 15. Next Generation Cancer Diagnostics Market Restraints
 Table 16. Global Next Generation Cancer Diagnostics Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Next Generation Cancer Diagnostics Market Share by Players (2020-2025)
 Table 18. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2024)
 Table 19. Ranking of Global Top Next Generation Cancer Diagnostics Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Next Generation Cancer Diagnostics Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Next Generation Cancer Diagnostics, Headquarters and Area Served
 Table 22. Global Key Players of Next Generation Cancer Diagnostics, Product and Application
 Table 23. Global Key Players of Next Generation Cancer Diagnostics, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Next Generation Cancer Diagnostics Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2020-2025)
 Table 27. Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2026-2031)
 Table 29. Global Next Generation Cancer Diagnostics Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2020-2025)
 Table 31. Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2026-2031)
 Table 33. North America Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Next Generation Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Next Generation Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Next Generation Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Next Generation Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Next Generation Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Next Generation Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Next Generation Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Cepheid Company Details
 Table 49. Cepheid Business Overview
 Table 50. Cepheid Next Generation Cancer Diagnostics Product
 Table 51. Cepheid Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 52. Cepheid Recent Development
 Table 53. Koninklijke Philips N.V Company Details
 Table 54. Koninklijke Philips N.V Business Overview
 Table 55. Koninklijke Philips N.V Next Generation Cancer Diagnostics Product
 Table 56. Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 57. Koninklijke Philips N.V Recent Development
 Table 58. F. Hoffmann-La Roche Ltd Company Details
 Table 59. F. Hoffmann-La Roche Ltd Business Overview
 Table 60. F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Product
 Table 61. F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 62. F. Hoffmann-La Roche Ltd Recent Development
 Table 63. Qiagen Company Details
 Table 64. Qiagen Business Overview
 Table 65. Qiagen Next Generation Cancer Diagnostics Product
 Table 66. Qiagen Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 67. Qiagen Recent Development
 Table 68. Novartis AG Company Details
 Table 69. Novartis AG Business Overview
 Table 70. Novartis AG Next Generation Cancer Diagnostics Product
 Table 71. Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 72. Novartis AG Recent Development
 Table 73. Abbott Company Details
 Table 74. Abbott Business Overview
 Table 75. Abbott Next Generation Cancer Diagnostics Product
 Table 76. Abbott Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 77. Abbott Recent Development
 Table 78. Thermo Fisher Scientific Company Details
 Table 79. Thermo Fisher Scientific Business Overview
 Table 80. Thermo Fisher Scientific Next Generation Cancer Diagnostics Product
 Table 81. Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 82. Thermo Fisher Scientific Recent Development
 Table 83. Opko Health Company Details
 Table 84. Opko Health Business Overview
 Table 85. Opko Health Next Generation Cancer Diagnostics Product
 Table 86. Opko Health Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 87. Opko Health Recent Development
 Table 88. Myriad Genetics Company Details
 Table 89. Myriad Genetics Business Overview
 Table 90. Myriad Genetics Next Generation Cancer Diagnostics Product
 Table 91. Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 92. Myriad Genetics Recent Development
 Table 93. Agilent Technologies Company Details
 Table 94. Agilent Technologies Business Overview
 Table 95. Agilent Technologies Next Generation Cancer Diagnostics Product
 Table 96. Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 97. Agilent Technologies Recent Development
 Table 98. GE Healthcare Company Details
 Table 99. GE Healthcare Business Overview
 Table 100. GE Healthcare Next Generation Cancer Diagnostics Product
 Table 101. GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 102. GE Healthcare Recent Development
 Table 103. PerkinElmer Company Details
 Table 104. PerkinElmer Business Overview
 Table 105. PerkinElmer Next Generation Cancer Diagnostics Product
 Table 106. PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 107. PerkinElmer Recent Development
 Table 108. Genomic Health Company Details
 Table 109. Genomic Health Business Overview
 Table 110. Genomic Health Next Generation Cancer Diagnostics Product
 Table 111. Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 112. Genomic Health Recent Development
 Table 113. Illumina Company Details
 Table 114. Illumina Business Overview
 Table 115. Illumina Next Generation Cancer Diagnostics Product
 Table 116. Illumina Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 117. Illumina Recent Development
 Table 118. Hologic Company Details
 Table 119. Hologic Business Overview
 Table 120. Hologic Next Generation Cancer Diagnostics Product
 Table 121. Hologic Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 122. Hologic Recent Development
 Table 123. Almac Group Company Details
 Table 124. Almac Group Business Overview
 Table 125. Almac Group Next Generation Cancer Diagnostics Product
 Table 126. Almac Group Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 127. Almac Group Recent Development
 Table 128. Janssen Global Services Company Details
 Table 129. Janssen Global Services Business Overview
 Table 130. Janssen Global Services Next Generation Cancer Diagnostics Product
 Table 131. Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 132. Janssen Global Services Recent Development
 Table 133. Sysmex Corporation Company Details
 Table 134. Sysmex Corporation Business Overview
 Table 135. Sysmex Corporation Next Generation Cancer Diagnostics Product
 Table 136. Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2020-2025) & (US$ Million)
 Table 137. Sysmex Corporation Recent Development
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Next Generation Cancer Diagnostics Picture
 Figure 2. Global Next Generation Cancer Diagnostics Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Next Generation Cancer Diagnostics Market Share by Type: 2024 VS 2031
 Figure 4. Next Generation Sequencing Features
 Figure 5. qPCR & Multiplexing Features
 Figure 6. DNA Microarrays Features
 Figure 7. Others Features
 Figure 8. Global Next Generation Cancer Diagnostics Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Next Generation Cancer Diagnostics Market Share by Application: 2024 VS 2031
 Figure 10. Hospitals Case Studies
 Figure 11. Clinics Case Studies
 Figure 12. Others Case Studies
 Figure 13. Next Generation Cancer Diagnostics Report Years Considered
 Figure 14. Global Next Generation Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Next Generation Cancer Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Next Generation Cancer Diagnostics Market Share by Region: 2024 VS 2031
 Figure 17. Global Next Generation Cancer Diagnostics Market Share by Players in 2024
 Figure 18. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Next Generation Cancer Diagnostics Revenue in 2024
 Figure 20. North America Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Next Generation Cancer Diagnostics Market Share by Country (2020-2031)
 Figure 22. United States Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Next Generation Cancer Diagnostics Market Share by Country (2020-2031)
 Figure 26. Germany Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Next Generation Cancer Diagnostics Market Share by Region (2020-2031)
 Figure 34. China Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Next Generation Cancer Diagnostics Market Share by Country (2020-2031)
 Figure 42. Mexico Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Next Generation Cancer Diagnostics Market Share by Country (2020-2031)
 Figure 46. Turkey Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Next Generation Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Cepheid Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 50. Koninklijke Philips N.V Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 51. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 52. Qiagen Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 53. Novartis AG Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 54. Abbott Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 56. Opko Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 57. Myriad Genetics Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 58. Agilent Technologies Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 59. GE Healthcare Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 60. PerkinElmer Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 61. Genomic Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 62. Illumina Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 63. Hologic Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 64. Almac Group Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 65. Janssen Global Services Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 66. Sysmex Corporation Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2020-2025)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Emerging Cancer Diagnostics Market Research Report 2024
Global Next Generation Tumor Genetic Testing Market Research Report 2024
Global Next Generation Oncology Devices Market Research Report 2024
Global Next Generation Gynecological Cancer Diagnostics Market Research Report 2024
Global Tumor Marker Testing Market Research Report 2024
Global Prostate Cancer Molecular Diagnostics Market Research Report 2024
Next Generation Breast Cancer Diagnostic and Screening Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Colon Cancer Molecular Diagnostics Market Research Report 2024
Global Lung Cancer Molecular Diagnostics Market Research Report 2024
Global Breast Cancer Molecular Diagnostics Market Research Report 2024
Global Cervical Cancer Molecular Diagnostics Market Research Report 2024
Global Oncology Based Molecular Diagnostics Market Insights Forecast to 2030
Global Cancer Genomic Testing Market Research Report 2024
Global Genomic Testing in Cancer Market Research Report 2024
Colorectal Cancer Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Precancer Molecular Diagnostics Market Research Report 2024
Global Ovarian Cancer Molecular Diagnostics Market Research Report 2024
Novel Cancer Diagnostic Solutions Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chest Cancer Molecular Diagnostics Market Research Report 2024
Global Bladder Cancer Molecular Diagnostics Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions